Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00002653
Other study ID # CDR0000064187
Secondary ID MRC-LEUK-MYEL-VI
Status Active, not recruiting
Phase Phase 3
First received November 1, 1999
Last updated December 18, 2013
Start date September 1993

Study information

Verified date October 2002
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating older patients with multiple myeloma.

PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without cyclophosphamide and prednisone in treating older patients with multiple myeloma.


Description:

Read more »
Read more »

Study Design

Allocation: Randomized, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
carmustine

cyclophosphamide

doxorubicin hydrochloride

melphalan

prednisone

Radiation:
radiation therapy


Locations

Country Name City State
United Kingdom MRC Myelomatosis Trials Office Birmingham England

Sponsors (1)

Lead Sponsor Collaborator
Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

See also
  Status Clinical Trial Phase
Completed NCT00568880 - Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT01137825 - Registry of Older Patients With Cancer
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Terminated NCT00608517 - Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil N/A
Completed NCT00478075 - Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00313625 - Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00898066 - S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease N/A
Completed NCT00951626 - A Standardized Nursing Intervention Protocol for HCT Patients N/A
Completed NCT00301951 - Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Phase 1
Terminated NCT00369291 - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Phase 1
Completed NCT00937183 - Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma N/A
Completed NCT00049374 - Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 2
Completed NCT00004072 - O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00003399 - Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00003398 - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Phase 4
Completed NCT00003396 - Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Phase 2
Active, not recruiting NCT00003163 - Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Phase 2
Terminated NCT00005641 - Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation Phase 2
Active, not recruiting NCT00002599 - Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Phase 3